69
Participants
Start Date
January 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
erlotinib
150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
pemetrexed
500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
cisplatin
cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
erlotinib
150 mg given orally (po), daily (QD), starting on the first day of the first cycle
The first affiliated hospital of Guangzhou MC, Guangzhou
Guangzhou Medical University
OTHER